The analyzed datasets show a higher expression of BAG3 in head and neck cancer, thyroid cancer, metastatic melanoma, bladder cancer, pancreatic cancer, mesothelioma, NSCLC, esophageal cancer, cervical cancer, lung cancer, and breast cancer, if compared with other nonfibrotic cancer types, such as lymphomas (p < .001; R = 0.72) (Figure 2C). This evidence concerns the gene BAG3 and metastatic melanoma.